Digest Network Come funziona
Network
/
Società
Av
Non verificato

Avenzo Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

31 comunicati stampa

Guarda tutti i comunicati
03/11/2026
Web e Social Network
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics to Participate at Upcoming Investor Conferences
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/10/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics to Present Preliminary Phase 1 Results from ORION-1 Study of AVZO-023, a Selective CDK4 Inhibitor, at the 2026 San Antonio Breast Cancer Symposium
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/10/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Fiere
Eventi
Industria
Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/10/2026
Mercato del lavoro
Oncologia
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
Avenzo Therapeutics Appoints Herb Cross as Incoming Chief Financial Officer
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/09/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics Expands Leadership Team
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/09/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics to Participate in the Upcoming Wells Fargo 21st Annual Healthcare Conference
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Mercato del lavoro
Associazioni/Professionisti
Oncologia
Salute
Risorse Umane
Farmaceutica
Biotecnologia
Avenzo Therapeutics Announces Appointment of Connie Wedel as Chief Human Resources Officer
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting
Fonte
Avenzo Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0